-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Healthy people vaccinated SARS-CoV-2 messenger RNA (mRNA) produced vaccine for COVID-19 of immune protection
.
However, little is known about the immune response induced by SARS-CoV-2 mRNA vaccine in immunosuppressed patients
COVID-19 immunity
Recently, a research article was published in the top medical journal Nature Medicine.
Researchers aim to explore multiple sclerosis (MS) patients (n=20) and healthy controls (n=10) receiving anti-CD20 antibody monotherapy.
After vaccination with BNT162b2 or mRNA-1273 mRNA vaccine, it induces the longitudinal response of antigen-specific antibodies, B cells and T cells
.
In most patients, treatment with anti-CD20 monoclonal antibodies (aCD20) significantly reduced peak-specific and receptor binding domain (RBD)-specific antibodies and memory B cell responses, as the duration of the last aCD20 treatment increased And the degree of B cell reconstitution is increased, and this effect is improved
.
In contrast, all MS patients treated with aCD20 developed antigen-specific CD4 and CD8 T cell immune responses after vaccination
.
The use of aCD20 treatment reversed the immune response, reduced the response of follicular helper T (TFH) cells in the circulation, and increased the CD8 T cell induction effect, while retaining the initiation of type 1 helper T (TH1) cells
These data clarify the overall view of the immune response induced by the SARS-CoV-2 vaccine in patients receiving aCD20 treatment, and provide important insights for coordinating the human immune response induced by the mRNA vaccine
.
The results of this study have guiding significance for the clinical decision-making and public health policies of immunosuppressed patients receiving aCD20 treatment
These data clarify the overall view of the immune response induced by the SARS-CoV-2 vaccine in patients receiving aCD20 treatment, and provide important insights for coordinating the human immune response induced by the mRNA vaccine
Original source:
Sokratis A.
Cellular and humoral immune responses following SARS- CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy in this message
